Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
UCB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
UCB SA, Medical Devices Deals, 2012 to YTD 2018 13
UCB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
UCB SA, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
UCB Acquires Rights to Midazolam Nasal Spray (USL261) from Proximagen 18
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 19
Venture Financing 20
Element Genomics Raises Funds through Venture Financing 20
Syndesi Therapeutics Raises USD21 Million in Series A Financing 21
Element Genomics Raises USD5 Million in Venture Financing 23
Lumos Pharma Raises USD34 Million in Series B Financing Round 24
Clementia Pharma Secures USD60 Million Venture Financing 26
Clementia Pharma Raises USD60 Million in Venture Financing 28
Dermira Raises USD51 Million In Series C Venture Financing 30
Private Equity 32
Paragon Partners to Acquire UCB Innere Medizin from UCB 32
Partnerships 33
Dr. Reddy’s Laboratories Enters into Distribution Agreement with UCB 33
Q-State Biosciences Enters into Research Agreement with UCB 34
NovAliX Enters into Agreement with UCB Biopharma 35
MC10 Enters into Agreement with UCB 36
MRC Technology, UCB and University of Leicester Enter into Agreement 37
UCB Enters into Research Agreement with Baylor College of Medicine 38
Evotec Partners with UCB 39
Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 40
Beryllium Enters into Agreement with UCB to Develop Drug Targets 41
Weill Cornell Medical College Enters Into Research Agreement With UCB For Drug Discovery Projects 42
Sanofi Enters Into Agreement With UCB For Drug Discovery 43
Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 44
Pharmathen Enters Into Co-Promotion Agreement With UCB For Allergy Products 45
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 46
UCB Enters Into Agreement With Lieber Institute To Develop Drugs For Cognitive Impairment 47
UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 48
UCB Enters Into Research Agreement With Five Prime Therapeutics 49
ConfometRx Enters Into Research Agreement With UCB To Discover Neuroscience Medicines 50
biOasis Technologies Enters Into Research Agreement With UCB 51
UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 52
UCB Expands Co-Development Agreement With Proteros biostructures For Protein X-Ray Crystallography 53
UCB Enters Into Co-Development Agreement With Harvard University 54
UCB Enters Into Co-Development Agreement With Imperial College London 55
UCB Enters Into Co-Development Agreement With Oxford University 56
Nodality Enters Into Co-Developement Agreement With UCB Pharma 57
Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 58
Otsuka Pharma Amends Co-Development Agreement With UCB 60
Licensing Agreements 62
UCB Enters into Licensing Agreement with Five Prime Therapeutics 62
Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 63
Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 64
Zai Lab Enters into Licensing Agreement with UCB 65
UCB Exercises Option for Licensing Agreement with Oncodesign 66
King’s College Enters into Licensing Agreement with UCB 67
King’s College London Enters Into Licensing Agreement with UCB 68
Neuropore Therapies Enters into Licensing Agreement with UCB 69
UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 70
UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 71
Equity Offering 72
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 72
Syndesi Therapeutics Spins Out from UCB 74
Dermira Raises USD7.5 Million in Private Placement of Shares 75
Wilex Completes Private Placement Of Shares For US$12.4 Million 77
Debt Offering 78
UCB Raises USD384 Million in Private Placement of 1.875% Bonds Due 2022 78
UCB Completes Private Placement Of 4.125% Bonds Due 2021 For US$473.2 Million 79
UCB Completes Public Offering Of Bonds For US$326 Million 80
Asset Transactions 81
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 81
Dr Reddy’s Labs Acquires Brands Portfolio of UCB for USD128 Million 82
Exemed Pharma Acquires Indian Production Facility of UCB 83
Atnahs Pharma Acquires Rights to Dipentum from UCB Pharma 84
Unither Pharma Acquires Pharma Manufacturing Plant from UCB 85
Acquisition 86
UCB Acquires Element Genomics 86
Biogen and UCB May Acquire Acorda Therapeutics 87
UCB Pharma Acquires Remaining Stake in Beryllium Discovery 88
Amphastar Pharma Acquires International Medication Systems from UCB Pharma for USD7.7 Million 89
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 90
UCB Acquires 51% Stake In Meizler Biopharma 92
UCB SA – Key Competitors 93
UCB SA – Key Employees 94
UCB SA – Locations And Subsidiaries 95
Head Office 95
Other Locations & Subsidiaries 95
Joint Venture 98
Recent Developments 99
Financial Announcements 99
Oct 30, 2018: UCB first nine months interim report 2018: UCB tracking well towards full year financial outlook 99
Jul 26, 2018: UCB half year report 2018: UCB continues its growth path 101
Apr 25, 2018: UCB First Three Months Interim Report 2018: UCB tracking well towards full year financial outlook 103
Feb 22, 2018: UCB Full Year Report 2017 105
Oct 20, 2017: UCB First Nine Months Interim Report 2017: Strong 9 months performance allows for increase of 2017 financial outlook 106
Jul 27, 2017: UCB with a strong first half year 2017 – giving rise to the financial outlook for 2017 107
Apr 24, 2017: UCB First Three Months Interim Report 2017: UCB with a good start into 2017 110
Corporate Communications 111
Mar 24, 2017: UCB General Meeting on 27 April 2017 111
Government and Public Interest 112
Jun 19, 2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma - UCB SA] 112
May 22, 2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority 113
Product News 114
09/21/2017: UCB’s anti-epileptic drug VIMPAT (lacosamide) receives EU approval for paediatric use 114
08/25/2017: Antiepileptic VIMPAT Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients 115
07/20/2017: UCB Pharma Receives CHMP Positive Opinion for Vimpat 116
Product Approvals 117
Sep 01, 2017: Restriction on prescription period lifted for antiepileptic VIMPAT Tablets 50 mg and 100 mg 117
Mar 13, 2017: UCB Pharmas Vimpat Rejects For Use Within NHS Scotland 118
Clinical Trials 119
Apr 26, 2017: Midazolam Nasal Spray (USL261) Phase 3 Trial Meets Primary Efficacy Endpoint In Patients With Seizure Clusters 119
Other Significant Developments 120
Oct 05, 2018: New online patent-search tool launched 120
Sep 05, 2018: New approach accelerates drug discovery 121
Mar 22, 2018: CIMZIA Label Update Marks Major Advance For Women Of Childbearing Age With Chronic Inflammatory Disease In U.S. 122
Mar 06, 2018: New online tool helps patients and physicians find our clinical studies 123
Appendix 124
Methodology 124
About GlobalData 124
Contact Us 124
Disclaimer 124
UCB SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
UCB SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
UCB SA, Deals By Therapy Area, 2012 to YTD 2018 11
UCB SA, Medical Devices Deals, 2012 to YTD 2018 13
UCB SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
UCB Acquires Rights to Midazolam Nasal Spray (USL261) from Proximagen 18
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 19
Element Genomics Raises Funds through Venture Financing 20
Syndesi Therapeutics Raises USD21 Million in Series A Financing 21
Element Genomics Raises USD5 Million in Venture Financing 23
Lumos Pharma Raises USD34 Million in Series B Financing Round 24
Clementia Pharma Secures USD60 Million Venture Financing 26
Clementia Pharma Raises USD60 Million in Venture Financing 28
Dermira Raises USD51 Million In Series C Venture Financing 30
Paragon Partners to Acquire UCB Innere Medizin from UCB 32
Dr. Reddy's Laboratories Enters into Distribution Agreement with UCB 33
Q-State Biosciences Enters into Research Agreement with UCB 34
NovAliX Enters into Agreement with UCB Biopharma 35
MC10 Enters into Agreement with UCB 36
MRC Technology, UCB and University of Leicester Enter into Agreement 37
UCB Enters into Research Agreement with Baylor College of Medicine 38
Evotec Partners with UCB 39
Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 40
Beryllium Enters into Agreement with UCB to Develop Drug Targets 41
Weill Cornell Medical College Enters Into Research Agreement With UCB For Drug Discovery Projects 42
Sanofi Enters Into Agreement With UCB For Drug Discovery 43
Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 44
Pharmathen Enters Into Co-Promotion Agreement With UCB For Allergy Products 45
Vectura Enters Into Co-Development Agreement With UCB For Biologic Immunomodulatory Product 46
UCB Enters Into Agreement With Lieber Institute To Develop Drugs For Cognitive Impairment 47
UCB Enters Into Drug Discovery Agreement With Crelux And 4SC Discovery 48
UCB Enters Into Research Agreement With Five Prime Therapeutics 49
ConfometRx Enters Into Research Agreement With UCB To Discover Neuroscience Medicines 50
biOasis Technologies Enters Into Research Agreement With UCB 51
UCB Enters Into R&D Agreement With Harvard University To Develop Immunology Drugs 52
UCB Expands Co-Development Agreement With Proteros biostructures For Protein X-Ray Crystallography 53
UCB Enters Into Co-Development Agreement With Harvard University 54
UCB Enters Into Co-Development Agreement With Imperial College London 55
UCB Enters Into Co-Development Agreement With Oxford University 56
Nodality Enters Into Co-Developement Agreement With UCB Pharma 57
Astellas Pharma Enters Into Co-Development Agreement With UCB For Cimzia 58
Otsuka Pharma Amends Co-Development Agreement With UCB 60
UCB Enters into Licensing Agreement with Five Prime Therapeutics 62
Stemline Therapeutics Enters into Licensing Agreement with UCB Biopharma 63
Syndax Pharma Enters into Licensing Agreement with UCB for UCB6352 64
Zai Lab Enters into Licensing Agreement with UCB 65
UCB Exercises Option for Licensing Agreement with Oncodesign 66
King's College Enters into Licensing Agreement with UCB 67
King’s College London Enters Into Licensing Agreement with UCB 68
Neuropore Therapies Enters into Licensing Agreement with UCB 69
UCB Enters Into Licensing Agreement With Medical Research Council Technology For Fibrosis Program 70
UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 71
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 72
Syndesi Therapeutics Spins Out from UCB 74
Dermira Raises USD7.5 Million in Private Placement of Shares 75
Wilex Completes Private Placement Of Shares For US$12.4 Million 77
UCB Raises USD384 Million in Private Placement of 1.875% Bonds Due 2022 78
UCB Completes Private Placement Of 4.125% Bonds Due 2021 For US$473.2 Million 79
UCB Completes Public Offering Of Bonds For US$326 Million 80
Merus Labs International Acquires Rights for Three Cardiovascular Products in Europe and Other Markets from UCB 81
Dr Reddy's Labs Acquires Brands Portfolio of UCB for USD128 Million 82
Exemed Pharma Acquires Indian Production Facility of UCB 83
Atnahs Pharma Acquires Rights to Dipentum from UCB Pharma 84
Unither Pharma Acquires Pharma Manufacturing Plant from UCB 85
UCB Acquires Element Genomics 86
Biogen and UCB May Acquire Acorda Therapeutics 87
UCB Pharma Acquires Remaining Stake in Beryllium Discovery 88
Amphastar Pharma Acquires International Medication Systems from UCB Pharma for USD7.7 Million 89
Lannett Acquires Kremers Urban Pharma for USD1.23 Billion 90
UCB Acquires 51% Stake In Meizler Biopharma 92
UCB SA, Key Competitors 93
UCB SA, Key Employees 94
UCB SA, Subsidiaries 95
UCB SA, Joint Venture 98
List of Figures
UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
UCB SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
UCB SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
UCB SA, Medical Devices Deals, 2012 to YTD 2018 13
